A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma

[1]  Gao-Min Liu,et al.  Identification of a four‐gene metabolic signature predicting overall survival for hepatocellular carcinoma , 2020, Journal of cellular physiology.

[2]  R. Deng,et al.  Clinical significance and function of RDH16 as a tumor‐suppressing gene in hepatocellular carcinoma , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  Zi-fei Yin,et al.  Sec62 promotes early recurrence of hepatocellular carcinoma through activating integrinα/CAV1 signalling , 2019, Oncogenesis.

[4]  L. Ming,et al.  Expression levels and prognostic values of annexins in liver cancer , 2019, Oncology letters.

[5]  Yongchang Zheng,et al.  DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma , 2019, Theranostics.

[6]  Yunfei Xu,et al.  Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway , 2019, EBioMedicine.

[7]  A. Lamort,et al.  Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight , 2019, Cells.

[8]  Gao-Min Liu,et al.  Identification of a six-gene signature predicting overall survival for hepatocellular carcinoma , 2019, Cancer Cell International.

[9]  Ting Lin,et al.  Seven-senescence-associated gene signature predicts overall survival for Asian patients with hepatocellular carcinoma , 2019, World journal of gastroenterology.

[10]  M. Kudo,et al.  Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan , 2019, Liver Cancer.

[11]  H. El‐Serag,et al.  Epidemiology and Management of Hepatocellular Carcinoma. , 2019, Gastroenterology.

[12]  D. Hu,et al.  Deregulation of the Genes that Are Involved in Drug Absorption, Distribution, Metabolism, and Excretion in Hepatocellular Carcinoma , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[13]  Haitao Zhao,et al.  A four‐gene‐based prognostic model predicts overall survival in patients with hepatocellular carcinoma , 2018, Journal of cellular and molecular medicine.

[14]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[15]  Jin Ding,et al.  SHP-1 Acts as a Tumor Suppressor in Hepatocarcinogenesis and HCC Progression. , 2018, Cancer research.

[16]  M. Kudo,et al.  Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis , 2018, Liver Cancer.

[17]  Zhenglu Wang,et al.  A six‐gene‐based prognostic signature for hepatocellular carcinoma overall survival prediction , 2018, Life sciences.

[18]  Amy S. Shah,et al.  A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL[S] , 2018, Journal of Lipid Research.

[19]  C. Gross,et al.  Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Olivier Gevaert,et al.  MethylMix 2.0: an R package for identifying DNA methylation genes , 2018, Bioinform..

[21]  Robert C. G. Martin,et al.  Multigene Signature Panels and Breast Cancer Therapy: Patterns of Use and Impact on Clinical Decision Making. , 2018, Journal of the American College of Surgeons.

[22]  D. Xie,et al.  AGBL2 promotes cancer cell growth through IRGM-regulated autophagy and enhanced Aurora A activity in hepatocellular carcinoma. , 2018, Cancer letters.

[23]  Qiang Yu,et al.  The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival. , 2018, Cancer research.

[24]  W. Liu,et al.  MAGEA6 promotes human glioma cell survival via targeting AMPKα1. , 2018, Cancer letters.

[25]  A. Gastaldelli,et al.  Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow‐up , 2017, Cytokine.

[26]  W. Syn,et al.  Osteopontin splice variants and polymorphisms in cancer progression and prognosis. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[27]  C. Rentero,et al.  Annexin A6 in the liver: From the endocytic compartment to cellular physiology. , 2017, Biochimica et biophysica acta. Molecular cell research.

[28]  T. Bestor,et al.  DNA methylation and DNA methyltransferases , 2017, Epigenetics & Chromatin.

[29]  Junfei Jin,et al.  Upregulation of hyaluronan-mediated motility receptor in hepatocellular carcinoma predicts poor survival. , 2015, Oncology letters.

[30]  Jian Huang,et al.  TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells , 2015, Oncotarget.

[31]  J. Llovet,et al.  Erratum for Advances in targeted therapies for hepatocellular carcinoma in the genomic era. [Nat Rev Clin Oncol. 2015] , 2015 .

[32]  J. Llovet,et al.  Advances in targeted therapies for hepatocellular carcinoma in the genomic era , 2015, Nature Reviews Clinical Oncology.

[33]  L. Hutchinson.  Lung cancer: Squiring immunotherapy to CheckMate , 2015, Nature Reviews Clinical Oncology.

[34]  V. Moreno,et al.  Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. , 2015, The oncologist.

[35]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[36]  J. Llovet,et al.  Advances in targeted therapies for hepatocellular carcinoma in the genomic era , 2015, Nature Reviews Clinical Oncology.

[37]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[38]  V. Baud,et al.  Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. , 2012, The Journal of clinical investigation.

[39]  Jessica Zucman-Rossi,et al.  KIF20A mRNA and its product MKlp2 are increased during hepatocyte proliferation and hepatocarcinogenesis. , 2012, The American journal of pathology.

[40]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[41]  Ching-Hui Yang,et al.  Mps1 Phosphorylation Sites Regulate the Function of Centrin 2 in Centriole Assembly , 2010, Molecular biology of the cell.

[42]  J. Rui,et al.  LAPTM4B‐35 is a novel prognostic factor of hepatocellular carcinoma , 2010, Journal of surgical oncology.

[43]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[44]  X. Nie,et al.  LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma , 2010, Journal of Cancer Research and Clinical Oncology.

[45]  T. Dale,et al.  Deficiency of Mbd2 Attenuates Wnt Signaling , 2008, Molecular and Cellular Biology.

[46]  E. Turley,et al.  Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? , 2008, Journal of Cell Science.

[47]  G. Raj,et al.  How to build and interpret a nomogram for cancer prognosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. Medema,et al.  Mps1 Phosphorylates Borealin to Control Aurora B Activity and Chromosome Alignment , 2008, Cell.

[49]  H. Törmä,et al.  13-cis-retinoic acid competitively inhibits 3 alpha-hydroxysteroid oxidation by retinol dehydrogenase RoDH-4: a mechanism for its anti-androgenic effects in sebaceous glands? , 2003, Biochemical and biophysical research communications.

[50]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[51]  Y. Jeng,et al.  Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation. , 2002, The American journal of pathology.

[52]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[53]  R. Tibshirani.  The lasso method for variable selection in the Cox model. , 1997, Statistics in medicine.